Recent Posts

• (29 May 2021) LPV/R, LPV,IFN,HCQ- did not improve the clinical status at day 15 in hospitalized patients

  May 31, 2021

  An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 https://doi.org/10.1016/j.cmi.2021.05.020 Adaptive, controlled trial (DisCoVeRy), add-on trial to Solidarity (NCT04315948, EudraCT2020-000936-23)- The intention-to-treat population included 583 participants (lopinavir/ritonavir, n=145; lopinavir/ritonavir-IFN-beta-1a,… Continue reading "(29 May 2021) LPV/R, LPV,IFN,HCQ- did not improve the clinical status at day 15 in hospitalized patients"

• (29 May 2021) Nintedanib-Lengths of MV were significantly shorter in the nintedanib group

  May 31, 2021

  Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by Coronavirus disease 2019: An interventional study https://doi.org/10.1016/j.ijid.2021.05.055 jRCTs051200036-This was an interventional study in which adult patients with COVID-19 requiring mechanical ventilation (MV) were consecutively enrolled. The primary… Continue reading "(29 May 2021) Nintedanib-Lengths of MV were significantly shorter in the nintedanib group"

• (28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild/moderate disease

  May 31, 2021

  Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1 NCT04545060-In this preplanned interim analysis, which included an intent-to-treat population of 583 patients (sotrovimab, 291; placebo, 292), the primary efficacy endpoint was met. The risk of Covid-19 progression was significantly reduced… Continue reading "(28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild/moderate disease"

• (27 May 2021) Favipiravir- FPV early had an impact on PCR negativity

  May 31, 2021

  Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study https://doi.org/10.1186/s12985-021-01577-1 A retrospective observational case-controlled cohort study was performed between March and September 2020, including adults with COVID-19 in a single-center in Turkey. We categorized… Continue reading "(27 May 2021) Favipiravir- FPV early had an impact on PCR negativity"

• (27 May 2021) Sofosbuvir- adding SOF/VEL to the standard of care did not improve the clinical status

  May 31, 2021

  Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial https://doi.org/10.1093/jac/dkab152 IRCT20130812014333N145-This single-centre, randomized, open-labelled, prospective clinical trial was done in patients with moderate to severe COVID-19 admitted to Farabi… Continue reading "(27 May 2021) Sofosbuvir- adding SOF/VEL to the standard of care did not improve the clinical status"

• (26 May 2021) Mycobacterium w-better clinical status distribution on days 14 and 21 compared to placebo

  May 28, 2021

  A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1 https://doi.org/10.1183/23120541.00059-2021 NCT04347174-Patients were randomised 1:1 to receive either 0.3 mL.day(-1) of Mw intradermally or a matching placebo for three consecutive days. The primary outcome of the study… Continue reading "(26 May 2021) Mycobacterium w-better clinical status distribution on days 14 and 21 compared to placebo"

• (26 May 2021) Methylprednisolone- high dose statistically significantly decreased the recovery time

  May 28, 2021

  Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia https://doi.org/10.1371/journal.pone.0252057 216 patients had Covid-19 pneumonia documented by ground-glass imaging and alveolar pressure / inspired oxygen fraction (PaFi) less than 300. 111 patients received dexamethasone (DXM) and 105 received methylprednisolone (MTP). Patients… Continue reading "(26 May 2021) Methylprednisolone- high dose statistically significantly decreased the recovery time"

• (25 May 2021) Plitidepsin- discharge rates by Days 8 and 15 were 56.8% and 81.8%

  May 28, 2021

  Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization https://www.medrxiv.org/content/10.1101/2021.05.25.21257505v1 EudraCT #2020-001993-31 NCT #04382066- Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A).… Continue reading "(25 May 2021) Plitidepsin- discharge rates by Days 8 and 15 were 56.8% and 81.8%"

• (24 May 2021) Tofacitinib-effective and safe for managing the cytokine release syndrome in COVID-19

  May 28, 2021

  Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19 https://doi.org/10.1016/j.pupt.2021.102039 Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to… Continue reading "(24 May 2021) Tofacitinib-effective and safe for managing the cytokine release syndrome in COVID-19"

• (23 May 2021) Methyl prednisolone- early high dose reduced mortality, length of hospitalization

  May 28, 2021

  Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis https://doi.org/10.1016/j.advms.2021.04.002 This is a single-center, retrospective study considering the patients with confirmed COVID-19 pneumonia admitted to our hospital between 9th March and 15(th) June… Continue reading "(23 May 2021) Methyl prednisolone- early high dose reduced mortality, length of hospitalization"